Related Experiment Video

Updated: May 24, 2026

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate

Tessa J Campbell1, Donald J Tindall, William D Figg

  • 1Molecular Pharmacology Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA.

Cancer Biology & Therapy
|February 17, 2012
PubMed

Insights

A new study reveals that the conversion of androstenedione (AD) to DHT, not testosterone, is the primary driver of castration-resistant prostate cancer (CRPC) progression. This finding challenges existing assumptions and offers new therapeutic targets for advanced prostate cancer.

Area of Science:

  • Oncology
  • Endocrinology
  • Biochemistry

Background:

  • Androgen deprivation therapy is standard for metastatic prostate cancer.
  • Most advanced prostate cancer progresses to castration-resistant prostate cancer (CRPC).
  • Understanding intratumoral androgen receptor (AR) agonist 5α-dihydrotestosterone (DHT) synthesis in CRPC is crucial.

Purpose of the Study:

  • To investigate the dominant pathway of intratumoral DHT synthesis in CRPC.
  • To identify the key enzymes and precursors involved in DHT production in CRPC.
  • To elucidate the mechanism driving CRPC progression.

Main Methods:

  • Analysis of DHT synthesis pathways in established human prostate cancer cell lines.
  • Examination of metastatic tumor samples from CRPC patients.
  • Biochemical assays to identify enzyme activity and precursor conversion.

Main Results:

  • Contrary to assumptions, testosterone is not the primary precursor to DHT in CRPC.
  • The conversion of androstenedione (AD) to 5α-dione, and subsequently to DHT, is the dominant pathway.
  • Steroid-5α-reductase isoenzyme 1 (SRD5A1) is identified as the key enzyme in this alternative pathway.
  • This AD→5α-dione→DHT pathway drives CRPC progression.

Conclusions:

  • The dominant pathway for DHT synthesis in CRPC involves androstenedione, not testosterone.
  • SRD5A1-mediated conversion of AD is critical for CRPC progression.
  • These findings provide new insights into CRPC pathogenesis and suggest novel therapeutic targets.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Related Concept Videos

Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...